Compare Illumina, Inc. (ILMN) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Rivian Automotive, Inc. — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Rivian Automotive, Inc. trades at $17.71 (market cap $24.95B). The key difference: Illumina, Inc. and Rivian Automotive, Inc. are close in size by market cap, and Illumina, Inc. is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | RIVN | |
|---|---|---|
Market Cap | $27.94B | $24.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $22.45 |
52-Week Low | $91.00 | $11.64 |
Enterprise Value | $29.33B | $26.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Rivian Automotive (RIVN) trades at $17.19, down 1.52% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company continues to post significant losses, with a net income margin of -63.62% for 2025, though revenue growth has been steady and recent quarterly EPS have beaten expectations. Cash flow remains negative, but the trend shows improvement from prior years. Analyst sentiment is mixed with a consensus price target of $19.22.
The outlook hinges on successful execution of the R2 vehicle launch and path to profitability. Investment opportunity lies in the potential for market share gains in the EV sector, but risks include high cash burn, competitive pressures, and reliance on capital markets for funding. The stock's performance will be closely tied to quarterly earnings and production updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
